Filing Flows › Royalty Pharma (RPRX) › Operating margin
Royalty Pharma (RPRX) operating margin by quarter
Royalty Pharma's operating margin was 59.5% in Q3 2026 (third quarter 2026), +39.8 pts from Q2 2026. Over the last 7 quarters it ranged from 19.7% (Q2 2026) to 94.0% (Q1 2025).
| Quarter | Operating margin | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | 59.5% | +39.8 pts | -10.6 pts |
| Q2 2026 | 19.7% | -69.5 pts | -16.5 pts |
| Q1 2026 | 89.3% | +26.8 pts | -4.7 pts |
| Q4 2025 | 62.4% | -7.7 pts | — |
| Q3 2025 | 70.1% | +33.9 pts | — |
| Q2 2025 | 36.3% | -57.7 pts | — |
| Q1 2025 | 94.0% | — | — |
Q3 2026 at a glance
Royalty Pharma, Q3 2026: revenue $690M (+13% year over year), operating margin 59.5%, net earnings $145M, operating cash flow $686M. The chart follows the revenue to costs, profit and cash.
Questions
What is Royalty Pharma's operating margin?
Royalty Pharma's operating margin was 59.5% in Q3 2026 (third quarter 2026), +39.8 pts from Q2 2026.
How has Royalty Pharma's operating margin changed?
Over the last 7 quarters it ranged from 19.7% (Q2 2026) to 94.0% (Q1 2025).